Arrowhead Pharmaceuticals' SWOT analysis: stock poised for potential breakthrough
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...
Arrowhead Pharmaceuticals director sells shares valued at $20,139
The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...
Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), ...
Business Wire16d
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
CNN1y
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms ...
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...
MedCity News4y
Horizon Therapeutics
Horizon Therapeutics is gaining global rights to an Arrowhead Pharmaceuticals drug for gout. The preclinical drug is the latest RNA interference program that Arrowhead has licensed to a larger ...
Investing1mon
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock faces pivotal year
The company's focus on developing medicines to treat intractable diseases by silencing the genes that cause them has positioned it as a key player in the RNAi therapeutics space. Arrowhead ...
Seeking Alpha17d
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely
Arrowhead hopes to secure its first drug approval in 2025, establishing proof of concept for its innovative approach to RNA therapeutics. In summary, then I'd be fairly optimistic that a >$3bn per ...
Investing1mon
B.Riley reiterates Buy rating on Arrowhead stock on siRNA therapeutics pipeline
The firm's analysts emphasized Arrowhead's dominance in the siRNA therapeutics market, particularly in cardiovascular-metabolic, pulmonary, and CNS/muscle delivery therapeutic categories.
Promising Pipeline and Strategic Collaborations Fuel Buy Rating for Silence Therapeutics
Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...
Investing1mon
B.Riley reiterates Buy rating on Arrowhead stock on siRNA therapeutics pipeline
The firm's analysts emphasized Arrowhead's dominance in the siRNA therapeutics market, particularly in cardiovascular-metabolic, pulmonary, and CNS/muscle delivery therapeutic categories. They pointed ...